ReviewClinical genetics2012
Familial breast cancer.
Review in Clinical genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed.
- Targeted Sequencing of the Mitochondrial Genome of Women at High Risk of Breast Cancer without Detectable Mutations in BRCA1/2.PloS one · 2015Trial
- Attributable breast cancer burden in Malaysia: mammographic density, lifestyle, and hereditary factors.Cancer causes & control : CCC · 2026Article
- Article
- Association of Genetic Risk Variants in SETBP1, FANCM, and LSP1 with Familial Breast Cancer in the Pakistani Pashtun Population.Pakistan journal of medical sciences · 2025Article
- Population-based study of recurrent DNA damage response gene variants in breast cancer cases.Breast cancer research and treatment · 2025Article
- Application of genetic testing criteria for hereditary breast cancer in South Africa.Breast cancer research and treatment · 2025Article
- Roles of Mesenchymal Stem Cells in Breast Cancer Therapy: Engineered Stem Cells and Exosomal Cell-Free Based Therapy.Current molecular medicine · 2025Review
- Longitudinal history of mammographic breast density and breast cancer risk by familial risk, menopausal status, and initial mammographic density level in a high risk cohort: a nested case-control study.Breast cancer research : BCR · 2024Article
- BRCA2 mutations in familial breast cancer with prostate cancer: a case report and literature review.Frontiers in oncology · 2024Article
- Comparative epidemiological study of breast cancer in humans and canine mammary tumors: insights from Portugal.Frontiers in veterinary science · 2023Article
- Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.Journal of cellular and molecular medicine · 2022Review
- Physical activity and sleep behaviour in women carrying BRCA1/2 mutations.Scientific reports · 2022Article
- A Prognostic Gene Signature for Hepatocellular Carcinoma.Frontiers in oncology · 2022Article
- Article
- Case Report: Next-Generation Sequencing-Based Detection in A Patient with Three Synchronous Primary Tumors.Frontiers in oncology · 2022Article
- Oral administration of tartrazine (E102) accelerates the incidence and the development of 7,12-dimethylbenz(a) anthracene (DMBA)-induced breast cancer in rats.BMC complementary medicine and therapies · 2021Article
- Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer.Breast (Edinburgh, Scotland) · 2021Article
- Identification and Characterization of NewGenes · 2021Article
- Association of Family History with the Development of Breast Cancer: A Cohort Study of 129,374 Women in KoGES Data.International journal of environmental research and public health · 2021Article
- Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.Familial cancer · 2021Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the localization and discovery of the first high-risk breast cancer (BC) genes in 1990, there has been a substantial progress in unravelling its familial component. Increasing numbers of women at risk of BC are coming forward requesting advice on their risk and what they can do about it. Three groups of genetic predisposition alleles have so far been identified with high-risk genes conferring 40-85% lifetime risk including BRCA1, BRCA2 and TP53. Moderate risk genes (20-40% risk) including PALB1, BRIP, ATM and CHEK2, and a host of low-risk common alleles identified largely through genome-wide association studies. Currently, only BRCA1, BRCA2 and TP53 are used in clinical practice on a wide scale, although testing of up to 50-100 gene loci may be possible in the future utilizing next-generation technology.
Indexed as
Identifiers
22356477What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.